

**PRESS RELEASE**

16 February 2023 14:20:00 CET

## **Senzime publishes prospectus relating to the rights issue**

Senzime AB (publ) ("Senzime" or "the Company") announced on 23 February 2023 that the Board of Directors had resolved on a new issue of shares of approximately SEK 100 million with preferential right for existing shareholders (the "Rights Issue"), which is covered to 90.7 per cent through subscription commitments, declarations of intent to subscribe and underwriting commitments. The Board of Directors' resolution of the Rights Issue was approved by the Extraordinary General Meeting today on 16 February 2023. The prospectus that has been prepared in connection with the Rights Issue has today on 16 February 2023 been approved and registered by the Swedish Financial Supervisory Authority, and is available in Swedish on Senzime's website, [www.senzime.com](http://www.senzime.com), the Swedish Financial Supervisory Authority's website, [www.fi.se](http://www.fi.se), as well as on Danske Bank's website, [www.danskebank.se/prospekt](http://www.danskebank.se/prospekt).

Subscription forms for subscription with and without subscription rights can be obtained from Senzime's website, [www.senzime.com](http://www.senzime.com), as well as on Danske Bank's website, [www.danskebank.se/prospekt](http://www.danskebank.se/prospekt).

In connection with the Rights Issue and the prospectus mentioned above, the Company has had the year-end report for the financial year 2022 *reviewed* (SWE: översiktligt granskad) by the Company's auditor. The year-end report and a separate report from the review is available at the Company's website. In connection hereto, it is noted that in the press release published on 23 January 2023 at 19:19 CET it was incorrectly stated that the year-end report for the financial year 2022 would be *audited* (where it should have said *reviewed*).

The upcoming Rights Issue in Senzime is expected to be completed around 24 March 2023. To secure that the Company has at least three months of working capital financing regardless of the Rights Issue, the Company has entered into a short-term loan of SEK 10 million with Danske Bank. Furthermore, some of the current shareholders have issued binding and interest-free credit facilities totalling SEK 25.9 million. The credit facilities and the short-term loan from Danske Bank are valid until 30 June 2023.

### **Advisers**

In connection with the Rights Issue, the Company has retained Danske Bank A/S, Danmark, Sverige Filial as Sole Global Coordinator and Bookrunner and Advokatfirman Lindahl KB as legal adviser to the Company.

This press release is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall govern.

## Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from someone else. No action has been taken, and no action will be taken, to allow a public offering in any jurisdiction other than Sweden. An invitation to eligible persons to subscribe for shares in the Company will only be made through the prospectus that the Company published today, 16 February 2023.

The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the "**United States**"), Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa or South Korea or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

Within the European Economic Area ("**EEA**"), no public offering is intended to be made in any member state other than Sweden. In other member states of the EEA where the Prospectus Regulation applies, an offer of securities may only be made in accordance with exemptions in the Prospectus Regulation and any implementing measures. In the United Kingdom, an offering of securities may only be made to qualified investors in accordance with exemptions in the Prospectus Regulation and applicable law in the United Kingdom. Persons in any member state of the EEA other than Sweden or in the United Kingdom who are not qualified investors under applicable law should not take any action based on this press release, nor should they rely on it.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. The Company has prepared and today published a prospectus for the Rights Issue. The Prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority (SWE: Finansinspektionen) being the national competent authority and is available on the Company's website. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be made solely on the basis of the information contained in the prospectus. Thus, an investor is advised to read the entire prospectus.

## Forward-looking statements

This press release may contain forward-looking information that reflects the Company's current views on future events and financial and operational development. Words such as "intend", "estimate", "expect", "may", "plan", "estimate" and other expressions that imply indications or predictions of future developments or trends, and which are not based on historical facts, constitute forward-looking information. By their nature, forward-looking statements involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking information is not a guarantee of future performance or development and actual results may differ materially from those expressed in forward-looking statements. The information, opinions and forward-looking statements expressed or implied herein speak only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.

## For further information, please contact:

---

Pia Renaudin, CEO of Sensime AB

Phone: +46 (0) 708 13 34 17, e-mail: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

Paula Treutiger, Head of Communication and IR

Phone: +46 (0) 733 66 65 99, e-mail: [paula.treutiger@senzime.com](mailto:paula.treutiger@senzime.com)

## About Sensime

---

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Sensime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://www.senzime.com).

*This information is information that Sensime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-16 14:20 CET.*

## Attachments

---

[Senzime publishes prospectus relating to the rights issue](#)